HRP20251268T1 - Postupci za liječenje hiperfenilalaninemije - Google Patents

Postupci za liječenje hiperfenilalaninemije

Info

Publication number
HRP20251268T1
HRP20251268T1 HRP20251268TT HRP20251268T HRP20251268T1 HR P20251268 T1 HRP20251268 T1 HR P20251268T1 HR P20251268T T HRP20251268T T HR P20251268TT HR P20251268 T HRP20251268 T HR P20251268T HR P20251268 T1 HRP20251268 T1 HR P20251268T1
Authority
HR
Croatia
Prior art keywords
sepiapterin
individual
pharmaceutically acceptable
salt
acceptable salt
Prior art date
Application number
HRP20251268TT
Other languages
English (en)
Croatian (hr)
Inventor
Niel SMITH
Original Assignee
Ptc Therapeutics Mp, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72827023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20251268(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ptc Therapeutics Mp, Inc. filed Critical Ptc Therapeutics Mp, Inc.
Publication of HRP20251268T1 publication Critical patent/HRP20251268T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HRP20251268TT 2019-09-25 2020-09-25 Postupci za liječenje hiperfenilalaninemije HRP20251268T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962905720P 2019-09-25 2019-09-25
EP20789788.5A EP4034122B1 (en) 2019-09-25 2020-09-25 Methods for treating hyperphenylalaninemia
PCT/US2020/052871 WO2021062264A1 (en) 2019-09-25 2020-09-25 Methods for treating hyperphenylalaninemia

Publications (1)

Publication Number Publication Date
HRP20251268T1 true HRP20251268T1 (hr) 2025-12-05

Family

ID=72827023

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20251268TT HRP20251268T1 (hr) 2019-09-25 2020-09-25 Postupci za liječenje hiperfenilalaninemije

Country Status (23)

Country Link
US (1) US20220362249A1 (cg-RX-API-DMAC7.html)
EP (1) EP4034122B1 (cg-RX-API-DMAC7.html)
JP (2) JP7661315B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220070477A (cg-RX-API-DMAC7.html)
CN (1) CN114650825A (cg-RX-API-DMAC7.html)
AU (1) AU2020353676B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022003719A2 (cg-RX-API-DMAC7.html)
CA (1) CA3150003A1 (cg-RX-API-DMAC7.html)
DK (1) DK4034122T3 (cg-RX-API-DMAC7.html)
ES (1) ES3041002T3 (cg-RX-API-DMAC7.html)
FI (1) FI4034122T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251268T1 (cg-RX-API-DMAC7.html)
HU (1) HUE073483T2 (cg-RX-API-DMAC7.html)
IL (1) IL291565B1 (cg-RX-API-DMAC7.html)
JO (1) JOP20220042A1 (cg-RX-API-DMAC7.html)
LT (1) LT4034122T (cg-RX-API-DMAC7.html)
MX (1) MX2022003585A (cg-RX-API-DMAC7.html)
PL (1) PL4034122T3 (cg-RX-API-DMAC7.html)
PT (1) PT4034122T (cg-RX-API-DMAC7.html)
RS (1) RS67295B1 (cg-RX-API-DMAC7.html)
SI (1) SI4034122T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500493T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021062264A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
US12691119B2 (en) 2021-02-09 2026-07-28 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
ES2586945T3 (es) * 2014-03-31 2016-10-19 Vasopharm Gmbh Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de dichas composiciones
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) * 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) * 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩

Also Published As

Publication number Publication date
MX2022003585A (es) 2022-04-19
ES3041002T3 (en) 2025-11-06
JP2022549834A (ja) 2022-11-29
JOP20220042A1 (ar) 2023-01-30
BR112022003719A2 (pt) 2022-05-31
DK4034122T3 (da) 2025-09-15
EP4034122A1 (en) 2022-08-03
FI4034122T3 (fi) 2025-10-08
RS67295B1 (sr) 2025-11-28
PT4034122T (pt) 2025-09-18
WO2021062264A1 (en) 2021-04-01
SMT202500493T1 (it) 2026-01-12
HUE073483T2 (hu) 2026-01-28
AU2020353676B2 (en) 2026-04-30
JP2025111476A (ja) 2025-07-30
IL291565B1 (en) 2026-04-01
SI4034122T1 (sl) 2025-12-31
KR20220070477A (ko) 2022-05-31
US20220362249A1 (en) 2022-11-17
CN114650825A (zh) 2022-06-21
EP4034122B1 (en) 2025-08-13
CA3150003A1 (en) 2021-04-01
PL4034122T3 (pl) 2026-01-26
IL291565A (en) 2022-05-01
AU2020353676A1 (en) 2022-04-14
LT4034122T (lt) 2025-11-10
JP7661315B2 (ja) 2025-04-14

Similar Documents

Publication Publication Date Title
FI4034122T3 (fi) Menetelmiä hyperfenyylialaninemian hoitamiseksi
JP2022549834A5 (cg-RX-API-DMAC7.html)
HRP20210239T1 (hr) Tetrahidrobiopterin za liječenje stanja povezanih s povišenim razinama fenilalanina
US4920122A (en) Pharmaceutical composition and method for the treatment of infantile autism
JP5469706B2 (ja) 新規な葉酸代謝拮抗薬の組み合わせ療法
US20050147665A1 (en) Pharmaceutical and nutritional compositions
AU2011215669B2 (en) Compositions and methods for treating depression
AU627041B2 (en) Improved nutritional formulation for the treatment of renal disease
US20250082597A1 (en) Method for treating tauopathy in the brain, brain stem and spinal column
US20060099239A1 (en) Dietary supplement for promoting removal of heavy metals from the body
WO2021216896A1 (en) Treatment of conditions associated with thyroid hormone
JP2021535131A5 (cg-RX-API-DMAC7.html)
JP2009514776A (ja) 5,10−メチレンテトラヒドロホラートの安定な医薬調合物
CN109715168A (zh) 用于治疗宿醉的组合物
MX2022012693A (es) Composicion que comprende metilfolato.
US20020010148A1 (en) Oral combinations of hydroxocobalamin and folic acid
JPH04287660A (ja) フッ素症を予防する組成物とその方法
US20080255098A1 (en) Compositions and Methods for Treatment of Psychiatric Disorders
JPH04342528A (ja) アルコール代謝およびアセトアルデヒド代謝促進剤
EP1148882B1 (en) Use of a plasma homocysteine content reducing agent for the reduction of the thromboembolic side effect risk induced by gestagen type hormones
EP1964551A1 (en) Compositions for the prevention and treatment of primary headache and migraine
AU2017397463A1 (en) Compositions and methods for treating depression
JP2006169221A (ja) おやすみサプリ
JPH09136833A (ja) 疲労回復のための組成物
JP2004051534A (ja) 抗金属アレルギー剤